HomeCompareFMEDX vs BTI

FMEDX vs BTI: Dividend Comparison 2026

FMEDX yields 17.73% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FMEDX wins by $25.8K in total portfolio value
10 years
FMEDX
FMEDX
● Live price
17.73%
Share price
$11.28
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.5K
Annual income
$5,247.63
Full FMEDX calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — FMEDX vs BTI

📍 FMEDX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFMEDXBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FMEDX + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FMEDX pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FMEDX
Annual income on $10K today (after 15% tax)
$1,507.09/yr
After 10yr DRIP, annual income (after tax)
$4,460.49/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, FMEDX beats the other by $2,091.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FMEDX + BTI for your $10,000?

FMEDX: 50%BTI: 50%
100% BTI50/50100% FMEDX
Portfolio after 10yr
$50.6K
Annual income
$4,017.13/yr
Blended yield
7.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

FMEDX
No analyst data
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FMEDX buys
0
BTI buys
0
No recent congressional trades found for FMEDX or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFMEDXBTI
Forward yield17.73%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$63.5K$37.7K
Annual income after 10y$5,247.63$2,786.64
Total dividends collected$33.8K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: FMEDX vs BTI ($10,000, DRIP)

YearFMEDX PortfolioFMEDX Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$12,473$1,773.05$11,299$598.92+$1.2KFMEDX
2$15,413$2,066.85$12,794$703.91+$2.6KFMEDX
3$18,879$2,386.94$14,518$829.07+$4.4KFMEDX
4$22,933$2,732.41$16,513$978.64+$6.4KFMEDX
5$27,640$3,102.01$18,827$1,157.84+$8.8KFMEDX
6$33,069$3,494.15$21,518$1,373.12+$11.6KFMEDX
7$39,291$3,906.97$24,657$1,632.46+$14.6KFMEDX
8$46,380$4,338.36$28,329$1,945.74+$18.1KFMEDX
9$54,412$4,786.05$32,637$2,325.33+$21.8KFMEDX
10$63,469$5,247.63$37,708$2,786.64+$25.8KFMEDX

FMEDX vs BTI: Complete Analysis 2026

FMEDXStock

Normally the fund invests at least 80% of assets in securities of disruptive medicine companies. Normally it invests primarily in equity securities. Companies within the disruptive medicine theme include but are not limited to those companies that, in the Adviser's opinion, are engaged in robotic surgery, gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based health care platforms, and consumer wellness. The fund is non-diversified.

Full FMEDX Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this FMEDX vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FMEDX vs SCHDFMEDX vs JEPIFMEDX vs OFMEDX vs KOFMEDX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.